logo-loader
viewScancell Holdings PLC

Scancell Holdings PLC 'delighted' with success of £6.1mln fundraiser

The cash will be used to accelerate the development of both the ImmunoBody and Moditope platform technologies that help the body’s own immune system fight cancer.

CancerHeadline.jpg
The firm's technology uses the body's immune system to fight cancer

Scancell Holdings PLC (LON:SCLP) said it had successfully raised £6.1mln via a placing and open offer of shares with new and existing investors.

The cash will be used to accelerate the development of both the ImmunoBody and Moditope platform technologies that help the body’s own immune system fight cancer.

The fundraise was done in two tranches. A total of £3.4mln-worth of stock was placed at 17p a share.

Existing shareholders were also given the opportunity to follow their money in what’s called an open offer, which brought in another £2.7mln.

Chairman John Chiplin said he was “delighted” at the response from investors.

Quick facts: Scancell Holdings PLC

Price: 6.4 GBX

LSE:SCLP
Market: LSE
Market Cap: £29.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Richard Goodfellow Presents on Behalf of Scancell at the Biotech Capital...

Richard Goodfellow Presents on Behalf of Scancell at the Biotech Capital Conference 

on 03/08/2016

2 min read